PHARMACEUTICALS related term(s) Drugs

Addresses

State of the Union: President Trump, S862–S866 [5FE], H1356–H1361 [5FE]

Amendments

Dept. of HHS: establish Fair Price Negotiation Program to reduce drug prices, penalize certain companies, and prevent excessive price increases and establish out-of-pocket caps for Medicare (H.R. 3), consideration (H. Res. 758), H10041 [11DE]

——— establish Fair Price Negotiation Program to reduce drug prices, penalize companies that refuse to negotiate, and prevent excessive price increases and establish out-of-pocket caps for Medicare (H.R. 3), H10167, H10202, H10204, H10205, H10207, H10208, H10210, H10211, H10214, H10215, H10216, H10217 [12DE]

Health: reduce prescription drug prices, facilitate entry of generic and biosimilar products into the market, strengthen Federal exchanges, and reverse extension of short-term health plans (H.R. 987), H3873, H3874, H3876, H3877, H3878, H3879, H3880, H3882, H3883, H3884, H3885, H3886, H3887, H3888, H3889, H3891, H3892, H3893, H3894, H3896, H3897, H3898, H3900, H3901 [16MY]

——— reduce prescription drug prices, facilitate entry of generic and biosimilar products into the market, strengthen Federal exchanges, and reverse extension of short-term health plans (H.R. 987), consideration (H. Res. 377), H3811 [15MY]

Analyses

Lower Drug Costs Now Act (H.R. 3), E1572 [10DE]

Articles and editorials

Price Controls Would Stifle Biotech Innovation, H10132 [12DE]

Bills and resolutions

Abortion: ensure that a woman seeking a chemical abortion is informed that it may be possible to reverse the intended effects of the abortion if the woman changes her mind (see H.R. 2010), H2938 [1AP]

——— prohibit chemical abortions performed without the presence of a health care provider (see H.R. 4935), H8678 [30OC]

Business and industry: prohibit biological product manufacurers from compensating biosimilar and interchangeable product companies to delay entry of biosimilar and interchangeable products into the market (see H.R. 1499), H2366 [5MR]

——— prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market (see S. 64), S103 [9JA] (see H.R. 1344), H2100 [25FE] (see H.R. 1499), H2366 [5MR]

——— prohibit prescription drug manufacturers from compensating other companies to delay entry of generic drugs, biosimilar biological products, or interchangeable biological products into the market (see H.R. 2375), H3302 [29AP]

——— shorten monopoly periods for prescription drugs that are the subjects of sudden price hikes (see H.R. 1188), H1582 [13FE]

Capitol Building and Grounds: authorize use of Hart Senate Office Building atrium for DEA National Drug Take Back Day event (see S. Res. 158), S2387 [10AP]

——— authorize use of Philip A. Hart Senate Office Building atrium for DEA National Prescription Drug Take Back Day (see S. Res. 359), S5841 [16OC]

CDC: provide for national campaign to raise awarenesss of the importance, and combat misinformation about, vaccines in order to increase vaccination rates (see S. 1619), S3059 [22MY]

——— provide for national system for surveillance of vaccine rates, authorize research on vaccine hesitancy, and increase public understanding of the benefits of immunizations (see H.R. 2862), H4063 [21MY]

Centers for Medicare & Medicaid Services: conduct study on antipsychotic prescribing practices in nonnursing home settings (see H.R. 1955), H2915 [28MR]

——— ensure home infusion therapy services are accessible to all Medicare beneficiaries regardless of the presence of a skilled professional (see H. Con. Res. 63), H7773 [18SE]

Colleges and universities: designate institutions of higher education that provide research, data, and leadership on continuous manufacturing as National Centers of Excellence in Continuous Pharmaceutical Manufacturing (see H.R. 4866), H8538 [28OC]

Contraceptives: establish certain duties for pharmacies to ensure provision of FDA-approved contraception (see S. 1086), S2328 [9AP] (see H.R. 2182), H3217 [9AP]

——— provide women greater access by increasing availability of contraceptives over-the-counter and allowing use of health savings accounts to purchase such products (see S. 930), S2087 [28MR]

DEA: allow community addiction treatment facilities and community mental health facilities to register to dispense controlled substances through telemedicine (see S. 2244), S5062 [24JY] (see H.R. 4131), H7481 [30JY]

——— amend certain regulations so that practitioners may not administer more than 3 days of medication to a person at one time when administering narcotics in order to relieve acute withdrawal symptoms (see H.R. 2281), H3255 [10AP]

——— authorize debarment of certain controlled substances registrants (see H.R. 4806), H8455 [23OC]

——— clarify definition of ‘‘imminent danger to the public health or safety’’ to restore authority to suspend a pharmaceutical distributor’s license under certain circumstances (see H.R. 4563), H8080 [27SE]

——— clarify process for registrants to exercise due diligence upon discovering a suspicious order (see H.R. 3878), H7239 [23JY]

——— convene a task force to recommend the most effective program to share data and implement real-time drug diversion prevention (see S. 2686), S6092 [23OC] (see H.R. 4814), H8455 [23OC]

——— deem drugs or other substances that act as mu opioid receptor agonists to be in Schedule I of the Controlled Substances Act, designating they have high potential for abuse and have no medical use (see H.R. 2580), H3500 [8MY]

——— provide information on best practices and strategies for responding in the event of a robbery of a pharmacy (see H.R. 4505), H8052 [26SE]

——— report certain information on distribution of opioids to assist in identifying suspicious orders and hold manufacturers and distributors accountable who fail to report and stop suspicious orders (see S. 3070), S7113 [17DE]

——— require health care professionals to certify they will not prescribe more than a seven-day supply of opioids as treatment for acute pain or provide refills as part of their registration to prescribe opioids (see S. 724), S1734 [7MR] (see H.R. 1614), H2583 [7MR]

——— restore ability to target pharmaceutical companies distributing opioids in certain communities by implementing a probable cause standard for intervention and striking the corrective action plan option (see S. 424), S1133 [7FE]

Dept. of Agriculture: improve Supplemental Nutrition Assistance Program support for women, infants, and children impacted by substance use disorder (see H.R. 5249), H9169 [21NO]

Dept. of Defense: develop a strategy to recruit and retain mental health providers and direct military departments to develop medication monitoring programs (see H.R. 1801), H2745 [14MR]

——— include in each national defense strategy steps to strengthen the U.S. industrial base and to assure an uninterrupted supply of medicines (see H.R. 4710), H8226 [17OC]

Dept. of HHS: add a new set of measures to Medicare Advantage program 5-star rating system in order to encourage increased access to biosimilar biological products (see H.R. 4629), H8101 [8OC]

——— address opioid drug abuse epidemic (see H.R. 2922), H4118 [22MY]

——— administer vaccinations for hepatitis A, at no cost to the inoculated, in certain areas at risk of a hepatitis A outbreak (see H.R. 2361), H3283 [25AP]

——— allow expedited approval of generic prescription drugs and temporary importation of prescription drugs during noncompetitive drug markets and drug shortages (see S. 844), S1899 [14MR]

——— allow importation by wholesalers, pharmacies, and individuals of safe and affordable drugs from FDA-certified foreign sellers (see S. 97), S142 [10JA] (see H.R. 447), H462 [10JA]

——— allow personal importation of safe and affordable drugs from approved pharmacies in Canada (see S. 61), S103 [9JA] (see H.R. 478), H463 [10JA]

——— approve cheaper generic versions of certain drugs if pharmaceutical manufacturers refuse to lower drug prices down to the median price at which the drugs are available in other countries (see S. 102), S142 [10JA] (see H.R. 465), H462 [10JA]

——— authorize State Opioid Response Grants and Tribal Opioid Response Grants programs (see H.R. 2466), H3404 [1MY]

——— authorize State Opioid Response Grants program and allow use of funding to address methamphetamine and cocaine abuse (see S. 1925), S4168 [20JN] (see H.R. 4111), H7480 [30JY]

——— carry out a program to address health crisis of insufficient vaccinations (see H.R. 3058), H4215 [3JN]

——— condition receipt by State and local entities of preventive health services grants on establishment of vaccination requirements for public school students in accordance with certain CDC recommendations (see H.R. 2527), H3447 [3MY]

——— conduct a study on impact of affordability of insulin on insulin-dependent individuals (see S. 2855), S6604 [14NO]

——— educate health care professionals and the public on biosimilar biological products (see S. 1681), S3106 [23MY] (see H.R. 4400), H7834 [19SE]

——— enhance efforts to address antibiotic resistance (see S. 2304), S5141 [29JY]

——— ensure doctors have access to patients’ treatment history to prevent addiction relapses or harmful drug interactions and protect confidentiality of substance use disorder patient records (see S. 1012), S2240 [3AP] (see H.R. 2062), H3067 [3AP]

——— ensure medications are affordable through increasing transparency, allowing Medicare to negotiate lower prices and importation of certain drugs, spurring innovation, and protecting competition (see S. 1801), S3363 [12JN]

——— establish an annual reference price for insulin products for purposes of Federal health programs (see S. 2817), S6475 [7NO] (see H.R. 5364), H9386 [9DE]

——— establish Fair Price Negotiation Program to reduce drug prices, penalize certain companies, and prevent excessive price increases and establish out-of-pocket caps for Medicare (H.R. 3), consideration (see H. Res. 758), H10015 [10DE]

——— establish Fair Price Negotiation Program to reduce drug prices, penalize companies that refuse to negotiate, and prevent excessive price increases and establish out-of-pocket caps for Medicare (see H.R. 3), H7834 [19SE]

——— establish Office of Drug Manufacturing to manufacture certain generic drugs in order to reduce prices, increase competition, and address shortages in the prescription drug market (see H.R. 5501), H12289 [19DE]

——— establish Prescription Safety Alert System to combat prescription drug abuse by collecting, maintaining, and providing to dispensers patients’ prescription and dispensing history (see H.R. 1845), H2761 [21MR]

——— establish reference prices for prescription drugs and require drug companies to offer drugs at such prices as condition of participation in Federal health programs (see S. 1987), S4566 [26JN] (see H.R. 3523), H5201 [26JN]

——— establish requirements relative to prescription drug benefits (see S. 657), S1659 [5MR]

——— establish State insulin assistance programs, hold manufacturers accountable for excessive insulin price increases, and promote market competition to drive down prices (see S. 2004), S4628 [27JN] (see H.R. 4010), H7464 [25JY]

——— extend floor on area wage index under inpatient prospective payment system and provide eligibility for discounted drug prices under 340B drug pricing program to certain sole community hospitals (see H.R. 1323), H2046 [22FE]

——— impose a fee on opioid manufacturers to fund an increase in drug addiction treatment capacity (see S. 1662), S3105 [23MY] (see H.R. 3105), H4341 [5JN]

——— improve access to pre-exposure prophylaxis (PrEP) to reduce transmission of HIV (see S. 1926), S4168 [20JN] (see H.R. 3815), H5999 [17JY]

——— incentivize low-cost drug options and generic competition and extend funding for community health centers, National Health Service Corps, teaching health centers and other public health programs (see H.R. 2700), H3788 [14MY]

——— increase maximum number of special masters allowed in U.S. Court of Federal Claims to hear cases under National Vaccine Injury Compensation Program (see S. 1638), S3104 [23MY] (see H.R. 3003), H4163 [23MY]

——— limit orphan drug exclusion under the discount drug program requiring drug manufacturers to provide drugs to eligible health care organizations at reduced prices (see H.R. 4538), H8054 [26SE]

——— mitigate drug shortages by prioritizing review of new drug applications, inspections, and reasons for shortages and assess national security threats associated with drug and ingredient shortages (see S. 2723), S6242 [29OC]

——— negotiate prices of prescription drugs furnished under Medicare part D and mandate production of generic versions of drugs if pharmaceutical companies fail to negotiate in good faith (see S. 377), S1131 [7FE] (see H.R. 1046), H1458 [7FE]

——— prohibit from treating any Medicaid-related funds recovered from pharmaceutical companies or drug distributors with respect to opioid litigation as an overpayment (see H.R. 5242), H9168 [21NO]

——— prohibit price gouging in the sale of drugs by requiring pharmaceutical companies to provide justification for price increases and penalize such companies if increases are deemed unreasonable (see S. 637), S1594 [28FE] (see H.R. 4158), H7488 [2AU]

——— require drug manufacturers to include printed inserts containing drug information when they ship their products to pharmacies (see H.R. 5198), H9120 [20NO]

——— require drug manufacturers to publicly justify unnecessary price increases (see S. 474), S1326 [13FE]

——— require drug manufacturers to submit a transparency and justification report prior to increasing certain drug prices (see S. 1391), S2770 [9MY] (see H.R. 2069), H3068 [3AP] (see H.R. 2296), H3263 [12AP]

——— require manufacturers of certain drugs, devices, biologicals, and medical supplies to report on product samples provided to certain health care providers (see H.R. 2064), H3067 [3AP]

——— require manufacturers to justify drug price spikes and high launch prices and report on drug, device, biological, and medical supply product samples provided to health care providers (see H.R. 2113), H3127 [8AP]

——— require persons who undertake federally funded research and development of drugs to enter into reasonable pricing agreements (see H.R. 4640), H8110 [11OC]

——— require pharmacies and insurance companies to improve transparency of prescription drug costs and prohibit drug manufacturers from charging U.S. consumers more for drugs than certain foreign customers (see S. 977), S2118 [1AP]

——— require pharmacies to disclose any differential between the cost of a prescription drug based on whether certain individuals use prescription drug coverage to acquire such drug (see H.R. 5442), H10306 [16DE]

——— support endemic fungal disease research, incentivize fungal vaccine development, and discover new antifungal therapies and diagnostics to fight infections such as valley fever (see S. 1567), S3004 [21MY] (see H.R. 2858), H4063 [21MY]

——— test the feasibility and outcomes of integrating a substance use disorder and behavioral health treatment locator tool into prescription drug monitoring programs of eligible States (see H.R. 3927), H7376 [24JY]

Dept. of Justice: make grants to State and local governments for programs to provide medication-assisted treatment to individuals incarcerated in the jurisdiction who are addicted to opioids (see S. 1983), S4566 [26JN] (see H.R. 3496), H5199 [26JN]

——— make procurement quotas for opioid analgesics publicly available to disclose applications requesting active ingredients and amount of opioids alloted to be produced by manufacturers (see S. 1366), S2742 [8MY] (see H.R. 2582), H3500 [8MY]

——— provide grants for drug disposal sites (see H.R. 3171), H4387 [10JN]

——— reauthorize Comprehensive Opioid Abuse Grant Program (see H.R. 1528), H2367 [5MR]

Dept. of State: develop and maintain an international diplomatic and assistance strategy to stop the flow of illicit opioids, including fentanyl, into the U.S. (see H.R. 2780), H3923 [16MY]

Dept. of Veterans Affairs: conduct review of deaths of certain veterans who committed suicide (see H.R. 100), H204 [3JA]

——— eliminate copayments for medicines relative to preventive health services (see S. 1573), S3004 [21MY] (see H.R. 3932), H7376 [24JY]

——— eliminate sunset date and expand eligibility for Veterans Choice Program, provide access to walk-in clinics, expand pharmacy operating hours, encourage peer reviews, and expand telemedicine (see H.R. 23), H201 [3JA]

——— ensure certain departmental medical facilities have physical locations for disposal of controlled substances or medications (see H.R. 4817), H8456 [23OC]

Diseases and disorders: facilitate effective research on, and treatment of, neglected tropical diseases through coordinated international efforts (see S. 2481), S5539 [17SE] (see H.R. 3460), H5165 [25JN]

——— facilitate effective research on, and treatment of, neglected tropical diseases, including Ebola, through coordinated domestic and international efforts (see H.R. 826), H1242 [28JA]

Drug abuse: recognize addiction as a disease and support efforts to prevent, treat, and destigmatize substance use disorder and addiction (see H. Res. 714), H9057 [19NO]

Drugs: allow State-based, market-oriented, prescription drug negotiations to lower drug prices, encourage competition, and increase consumer choice and access (see H.R. 2038), H2986 [2AP]

——— create a mechanism whereby insulin manufacturers may sell directly to consumers at current net prices (see H.R. 5382), H10015 [10DE]

——— develop national cannabis research agenda, collect data on cannabis use and impacts on health outcomes, change controlled substance classification of cannabis, and streamline DEA approval of research (see S. 2400), S5248 [31JY] (see H.R. 4322), H7705 [12SE]

——— encourage development and use of new antimicrobial drugs in order to treat antibiotic-resistant infections (see S. 1712), S3215 [4JN] (see H.R. 4100), H7479 [30JY]

——— end Federal ban of medical marijuana, allow importation of certain derivatives, enable medicinal research, and allow prescription to veterans (see H.R. 127), H205 [3JA]

——— establish an interactive dashboard to allow the public to review information on price and utilization of prescription drugs purchased by Federal programs (see S. 709), S1733 [7MR]

——— facilitate responsible, informed dispensing of controlled substances and other prescribed medications (see H.R. 4810), H8455 [23OC]

——— improve medical research on marijuana by simplifying registration process to conduct research, facilitating access for such research, and allowing private manufacture and distribution for research purposes (see H.R. 3797), H5998 [17JY]

——— increase number of cannabis manufacturers registered under Controlled Substances Act for legitimate research purposes and allow VA health care providers to recommend federally-approved cannabis clinical trials (see H.R. 601), H674 [16JA]

——— lower cost of prescription drugs (see H.R. 3947), H7377 [24JY]

——— prohibit pharmacy benefit managers and insurers from receiving rebates for insulin products for which the manufacturer has complied with list price reduction requirements and require certain deductible waivers (see S. 2199), S4966 [22JY] (see H.R. 4906), H8594 [29OC]

——— provide assistance to States and localities affected by the opioid epidemic and improve delivery of essential services to individuals with substance use disorders and their families (see S. 1365), S2742 [8MY] (see H.R. 2569), H3499 [8MY]

——— reform prescription drug pricing and reduce out-of-pocket costs by ensuring consumers benefit from negotiated rebates by requiring coinsurance obligations be set as a percentage of a drug’s net price not list price (see S. 1384), S2769 [9MY] (see H.R. 3805), H5998 [17JY]

——— require disclosure of list prices of prescription drugs and biological products in direct-to-consumer television advertising (see H.R. 3327), H4771 [18JN]

——— require drug manufacturers to disclose prices of prescription drugs in any direct-to-consumer advertising and marketing to practitioners of a drug (see H. Con. Res. 55), H7377 [24JY]

——— require National Academy of Medicine study on determining reasonable drug prices and establish Drug Affordability and Access Committee to issue reasonable pricing determination for each drug (see S. 2387), S5248 [31JY]

——— require reporting on prescription drug expenditures under group health plans and on prescription drug price changes (see S. 1664), S3105 [23MY] (see H.R. 5239), H9168 [21NO]

——— require use of prescription drug monitoring programs and facilitate information sharing among States that receive Federal funding to combat opioid abuse (see S. 516), S1383 [14FE] (see H.R. 3974), H7463 [25JY]

——— streamline, coordinate and expand research and foster increased communication between doctors and patients relative to cannabidiol and other marijuana components and their medical benefits (see S. 2032), S4628 [27JN]

FDA: address abuse of citizen petition process by brand drug manufacturers (see S. 660), S1659 [5MR]

——— allow for importation of affordable and safe insulin by wholesale distributors, pharmacies, and individuals (see H.R. 1478), H2314 [28FE]

——— allow rejection of a citizen petition if it is believed the primary purpose of the petition is to delay approval of a pending drug application and refer such petitioners to the FTC (see S. 1169), S2433 [11AP] (see H.R. 2455), H3404 [1MY]

——— amend exclusivity period granted to a first generic drug application (see S. 3092), S7156 [18DE]

——— amend mission statement to require the agency to address the nation’s prescription opioid addiction epidemic (see S. 417), S1133 [7FE]

——— clarify process for denying certain petitions whose primary purpose is to delay approval of an application submitted relative to certain drugs (see H.R. 2387), H3303 [29AP]

——— clarify regulatory framework relative to certain nonprescription drugs that are marketed without an approved new drug application (see S. 2740), S6299 [30OC] (see H.R. 269), H280 [8JA] (see H.R. 3443), H5075 [24JN]

——— clarify types of patents on safe and effective drug list, require list of applicable exclusivities for listed drugs, update patent sponsor requirements, and reform patent list guidelines (see S. 1617), S3059 [22MY] (see H.R. 1503), H2366 [5MR]

——— codify policy of requiring drug products to contain an active moiety that has not been used in a previously approved product in granting new chemical entity exclusivity (see S. 1636), S3104 [23MY]

——— ensure eligible product developers have competitive access to approved drugs and licensed biological products to enable development and testing of new products (see H.R. 985), H1362 [5FE]

——— ensure valid generic drugs may enter the market by removing generic drug exclusivity period from any generic company that enters into pay-for-delay settlements with brand-name drug manufacturers (see H.R. 1506), H2366 [5MR]

——— establish a time-limited conditional approval pathway, subject to specific obligations, for certain drugs (see S. 3133), S7208 [19DE] (see H.R. 5497), H12289 [19DE]

——— establish procedures relative to approval of opioid drugs (see S. 418), S1133 [7FE]

——— expand tropical disease product priority review voucher program to encourage treatments for Middle East respiratory syndrome, Nipah, and Rift Valley fever (see H.R. 4553), H8080 [27SE]

——— hold pharmaceutical companies accountable for dubious marketing and distribution of opioid products and for their role in creating and exacerbating the opioid epidemic (see S. 1584), S3005 [21MY] (see H.R. 2917), H4118 [22MY]

——— improve regulation of abortion drugs by prohibiting approval of new drugs, preventing labeling changes of existing drugs, and preventing providers from dispensing drugs remotely, by mail, or telemedicine (see S. 3072), S7113 [17DE] (see H.R. 4399), H7834 [19SE]

——— increase competition in generic drug market by removing barriers for a generic drug to come to market by curbing patent manipulation by brand name drug manufacturers (see S. 1209), S2435 [11AP] (see H.R. 3812), H5999 [17JY]

——— increase competition in generic drug market by removing barriers for a second generic drug to come to market created by exclusivity period granted to a first generic drug application (see H.R. 938), H1341 [31JA]

——— invest in qualified clinical testing for high-risk, high-reward drugs that address unmet medical needs to treat rare and life-threatening diseases (see H.R. 5402), H10123 [11DE]

——— limit exclusive approval or licensure of orphan drugs (see H.R. 4712), H8226 [17OC]

——— make permanent the policy to speed up time for biosimilar products to get approved and made available to consumers (see S. 1140), S2432 [11AP] (see H.R. 2011), H2938 [1AP]

——— permanently reauthorize Rare Pediatric Disease Designation Program to issue priority review vouchers to encourage treatments for rare pediatric diseases (see H.R. 4439), H7865 [20SE]

——— prevent abuse of dextromethorphan by restricting over-the-counter sales of cough medicines to teenagers and prohibiting bulk distribution of unfinished dextromethorphan to unauthorized persons (see H.R. 863), H1332 [30JA]

——— prevent inter partes review process for challenging patents from diminishing competition in the pharmaceutical industry and provide incentives for drug innovation (see S. 344), S919 [6FE] (see H.R. 990), H1389 [6FE]

——— prohibit abusive delay tactics by pharmaceutical companies to block entry of generic drugs and biosimilar biological products from the market (see S. 340), S867 [5FE] (see H.R. 965), H1361 [5FE]

——— prohibit opioids from being labeled for intended use to treat long-term chronic pain, except for cancer pain, end-of-life care, or when other pain management treatments are inadequate (see S. 2089), S4806 [11JY]

——— provide for a pathway for chemically synthesized insulin to be approved under an abbreviated new drug application (see H.R. 4244), H7558 [9SE]

——— provide for an accelerated approval pathway for certain drugs that are authorized to be lawfully marketed in other countries (see S. 658), S1659 [5MR]

——— provide for publication of a list of licensed biological products (see H.R. 1520), H2366 [5MR]

——— provide for reciprocal marketing approval of certain drugs, biological products, and devices that are authorized to be lawfully marketed abroad (see S. 2161), S4947 [18JY]

——— reauthorize innovation projects (see H.R. 4633), H8110 [11OC]

——— require label of drugs with an increased risk of suicide or depression to prominently detail those side effects (see H.R. 4404), H7834 [19SE]

——— require labeling of country of origin of a drugs active ingredients (see H.R. 5381), H10015 [10DE]

——— require labels of drugs that contain an ingredient that is derived directly or indirectly from a gluten-containing grain to identify each such ingredient (see S. 3021), S6992 [11DE] (see H.R. 2074), H3068 [3AP]

——— require manufacturers of approved biological products to disclose and list patents, biosimilarity, and exclusivity information relative to their products and promote biosimilar competition (see S. 659), S1659 [5MR] (see H.R. 4850), H8457 [23OC]

——— require warning labels to be affixed to prescription opioid containers or packaging stating such drugs can cause dependence, addiction, and overdose (see S. 1449), S2815 [14MY] (see H.R. 2732), H3789 [14MY]

——— restrict direct-to-consumer drug advertising (see H.R. 4106), H7480 [30JY]

——— revoke approval of one opioid pain medication for each new opioid pain medication approved (see S. 419), S1133 [7FE]

——— shorten exclusivity period for brand name biological products (see H.R. 3379), H5005 [20JN]

——— shorten monopoly periods for prescription drugs that are subjects of sudden price hikes (see S. 366), S919 [6FE]

——— speed up approvals of lower-cost, generic, and ‘‘follow-on’’ insulin products (see S. 2103), S4807 [11JY] (see H.R. 5444), H10608 [17DE]

——— strengthen regulation of compounding drugs by pharmacies (see H.R. 1959), H2915 [28MR]

——— update labeling of certain drugs with outdated labeling (see S. 1897), S3843 [19JN]

FEC: prohibit a separate segregated fund of a corporation which manufactures opioids from making contributions or expenditures in connection with Federal elections (see H.R. 5196), H9120 [20NO]

Federal aid programs: recognize essential benefit of Medicare and Social Security programs to current enrollees and strengthen such programs for future generations (see H. Res. 59), H719 [17JA]

Federal employees: remove limitations on Federal employment for individuals legally using marijuana according to laws of the State in which they reside (see H.R. 1687), H2679 [12MR]

FTC: deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar and foster competition and facilitate review of drug petitions filed in good faith (see S. 1224), S2485 [29AP] (see H.R. 2374), H3302 [29AP]

——— issue rules to promote competition and help consumers save money by giving them freedom to choose where they buy prescription pet medications (see S. 1290), S2613 [2MY] (see H.R. 1607), H2582 [7MR]

——— prohibit anticompetitive use of patents by drug product manufacturers (see S. 1416), S2770 [9MY] (see H.R. 4398), H7834 [19SE] (see H.R. 5133), H8958 [18NO]

——— study role of intermediaries in the pharmaceutical supply chain and merger activity and provide Congress with appropriate policy recommendations (see S. 1227), S2485 [29AP] (see H.R. 2376), H3302 [29AP]

GAO: evaluate and report on the in-patient and outpatient drug treatment capacity, availability, and needs of the U.S. (see H.R. 1303), H2038 [15FE]

——— study role pharmaceutical benefit managers play in the pharmaceutical supply chain and provide Congress with appropriate policy recommendations (see S. 1532), S2924 [16MY] (see H.R. 3223), H4626 [12JN]

Health: address high costs of health care, prescription drugs, and health insurance coverage (see H.R. 1332), H2100 [25FE]

——— anniversary of eradication of smallpox and recognition of importance of vaccinations and immunizations (see H. Res. 592), H7989 [25SE]

——— exempt sunscreen from over-the-counter medication bans in schools, encourage community and youth-related entities to provide access to sunscreen and sun-protective clothing, and teach sun-safe behaviors (see H. Res. 323), H3270 [15AP]

——— lower health care costs by ending surprise medical bills, reducing drug prices, and improving health care transparency, public health, and exchange of health information (see S. 1895), S3843 [19JN]

——— promote transparency in health care pricing (see H.R. 1409), H2271 [27FE]

——— recognize importance of vaccinations and immunizations (see S. Res. 165), S2435 [11AP] (see H. Res. 179), H2368 [5MR]

——— reduce prescription drug prices, facilitate entry of generic and biosimilar products into the market, strengthen Federal exchanges, and reverse extension of short-term health plans (H.R. 987), consideration (see H. Res. 377), H3787 [14MY]

——— require certain drug manufacturers entering into settlement agreements for violations of law to make supplemental payments to be used to increase medical research funding (see H.R. 5031), H8739 [8NO]

——— support the right to affordable, quality health care (see S. Res. 273), S4729 [9JY]

Health care professionals: improve and expand training for future and current physicians and mid-level health care providers on treating pain and prescribing opioids (see H. Con. Res. 8), H1283 [29JA]

——— require certain practitioners authorized to prescribe controlled substances to complete continuing education (see S. 1448), S2815 [14MY] (see H.R. 2734), H3789 [14MY]

Insurance: bring stability to the individual insurance market, make insurance coverage more affordable, lower prescription drug prices, and improve Medicaid (see S. 3), S19 [3JA]

——— ensure common medications, devices, and screenings used to treat chronic conditions are covered without out-of-pocket costs (see H.R. 4457), H7900 [24SE]

——— establish a public health plan (see S. 981), S2188 [2AP] (see H.R. 2000), H2937 [1AP]

——— require a group health plan to provide an exceptions process for any medication step therapy protocol (see S. 2546), S5706 [25SE] (see H.R. 2279), H3255 [10AP]

——— require group health plans and group or individual health insurance coverage to provide coverage for over-the-counter contraceptives (see S. 1847), S3476 [13JN] (see H.R. 3296), H4700 [14JN]

——— require health insurance providers to cover oral cancer drugs on terms no less favorable than for cancer medications administered by a health care provider (see S. 741), S1792 [12MR] (see H.R. 1730), H2716 [13MR]

——— require health plan oversight of pharmacy benefit manager services (see H.R. 5304), H9256 [4DE]

Medicaid: exclude authorized generic drugs from calculation of average manufacturer price for purposes of drug rebate program (see S. 1785), S3319 [11JN] (see H.R. 3276), H4694 [13JN]

——— expand permitted uses of drug price information disclosed to States under drug rebate program to make prescription drugs more affordable (see S. 2252), S5062 [24JY]

——— extend certain spousal impoverishment protections, provide State option of coordinated care for children with medically complex conditions, and prevent misclassification of drugs in drug rebate program (see H.R. 1839), H2760 [21MR]

——— improve transparency and prevent use of abusive spread pricing and related practices (see H.R. 5281), H9221 [3DE]

——— prevent misclassification of drugs for purposes of the drug rebate program (see S. 205), S586 [24JA] (see H.R. 937), H1341 [31JA]

——— prohibit States receiving Federal medical assistance for medication-assisted treatment for substance use disorders from imposing utilization control policies or procedures (see H.R. 3925), H7241 [23JY]

——— remove matching requirement for a territory to use specially allocated Federal funds for Medicare covered part D drugs for low-income individuals (see H.R. 2172), H3216 [9AP] (see H.R. 4699), H8198 [16OC]

——— sunset the limit on maximum rebate amount for single source drugs and innovator multiple source drugs (see H.R. 107), H205 [3JA]

Medicare: adjust part D prescription drug cost-sharing reductions for low-income individuals (see H.R. 2757), H3841 [15MY]

——— allow prescription drug plan sponsors and Medicare Advantage organizations to share with enrollees a portion of savings from switching to lower cost therapeutic alternative medications (see S. 3000), S6904 [9DE]

——— allow the Dept. of HHS to negotiate lower covered part D prescription drug prices for beneficiaries (see S. 62), S103 [9JA]

——— clarify treatment of pass-through status under outpatient payment system for certain drugs (see H.R. 5057), H8783 [12NO]

——— combat opioid crisis by promoting access to non-opioid treatments in the hospital outpatient setting (see S. 3067), S7113 [17DE] (see H.R. 5172), H9056 [19NO]

——— coordinate programs to prevent and treat obesity (see S. 595), S1593 [28FE] (see H.R. 1530), H2367 [5MR]

——— deliver a meaningful drug benefit and lower prescription drug prices (see S. 2650), S5922 [21OC] (see H.R. 4769), H8297 [21OC]

——— eliminate cost-sharing for biosimilar biological products furnished under part B (see H.R. 4597), H8089 [1OC]

——— eliminate resource requirement for low-income subsidy eligibility under part D (see H.R. 4628), H8101 [8OC]

——— enhance prescription drug affordability by expanding access to assistance with out-of-pocket costs under part D for low-income seniors and individuals with disabilities (see S. 691), S1733 [7MR] (see H.R. 4583), H8088 [1OC]

——— ensure equal access of beneficiaries to community pharmacies in underserved areas as network pharmacies under Medicare prescription drug coverage (see H.R. 4946), H8717 [31OC]

——— ensure equitable payment for, and beneficiary access to, diagnostic radiopharmaceuticals under hospital outpatient prospective payment system (see H.R. 3772), H5910 [16JY]

——— establish Medicare for America program to provide comprehensive health insurance coverage for all U.S. citizens (see H.R. 2452), H3404 [1MY]

——— establish part E public health plans available to everyone (see S. 1261), S2569 [1MY] (see H.R. 2463), H3404 [1MY]

——— expand eligibility for low-income subsidies under part D (see H.R. 4620), H8101 [8OC]

——— extend coverage of immunosuppressive drugs for kidney transplant patients (see H.R. 5534), H12297 [23DE]

——— improve efficiency of appeals process (see S. 3078), S7113 [17DE]

——— make premium and cost-sharing subsidies available to low-income part D beneficiaries residing in Puerto Rico or other U.S. territories (see S. 3029), S7026 [12DE] (see H.R. 4195), H7511 [20AU]

——— negotiate prices of excessively costly life-sustaining prescription drugs (see H.R. 5039), H8783 [12NO]

——— permanently authorize Limited Income Newly Eligible Transition (LI NET) Program to provide transitional coverage and retroactive part D prescription drug coverage for certain low-income individuals (see S. 1999), S4627 [27JN] (see H.R. 3029), H4174 [28MY]

——— prevent catastrophic out-of-pocket spending on prescription drugs for seniors and individuals with disabilities (see S. 475), S1326 [13FE]

——— prohibit prescription drug plan sponsors and Medicare Advantage prescription drug organizations from retroactively reducing payment on clean claims submitted by pharmacies (see S. 988), S2189 [2AP] (see H.R. 789), H1211 [24JA] (see H.R. 803), H1217 [25JA]

——— promote access to opioid treatments and require coverage of medication assisted treatment, overdose reversal medications, and recovery support services by health plans without cost-sharing requirements (see S. 1424), S2786 [13MY]

——— provide a monthly out-of-pocket cost-sharing maximum for enrollees who incur a significant portion of costs for covered part D drugs towards the annual out-of-pocket threshold during a month (see S. 2911), S6718 [20NO]

——— provide certain low-income territorial residents with automatic eligibility for premium and cost-sharing subsidies (see H.R. 4666), H8111 [11OC]

——— provide coverage for generic and biosimilar medications on part D plan formularies and ensure generic drugs are placed on formulary tiers so beneficiaries are not charged brand name drug prices (see H.R. 4913), H8677 [30OC]

——— provide coverage of addiction counselor services under part B (see S. 2412), S5311 [1AU]

——— provide for a cap on beneficiary liability under part D (see H.R. 4649), H8111 [11OC]

——— provide for a temporary payment increase for certain biosimilar biological products to encourage development and use of such products (see H.R. 4455), H7865 [20SE]

——— provide for automatic qualification of certain Medicaid beneficiaries for premium and cost-sharing subsidies under part D (see H.R. 4661), H8111 [11OC]

——— provide for certain rules on treatment of eligible retirement plans in determining eligibility of individuals for premium and cost-sharing subsidies under part D (see H.R. 4655), H8111 [11OC]

——— provide for distribution of additional residency positions to help combat the opioid crisis (see S. 2892), S6669 [19NO] (see H.R. 2439), H3403 [1MY] (see H.R. 3414), H5036 [21JN]

——— provide for intelligent assignment of certain subsidy eligible individuals auto-enrolled under prescription drug plans and Medicare Advantage prescription drug plans (see H.R. 4669), H8111 [11OC]

——— provide for negotiation of lower covered part D drug prices on behalf of beneficiaries and establishment and application of a formulary by the Dept. of HHS under part D (see S. 99), S142 [10JA] (see H.R. 448), H462 [10JA]

——— provide for pharmacy benefits manager standards under the prescription drug program and Medicare Advantage program to further transparency of payment methodology of pharmacies (see H.R. 1035), H1458 [7FE]

——— provide greater transparency of discounts provided by drug manufacturers by establishing requirements for pharmacy-negotiated price concessions (see S. 2247), S5062 [24JY]

——— provide greater transparency of discounts provided by drug manufacturers by requiring Pharmacy Benefit Managers to disclose aggregate rebates and what proportion of those rebates go to beneficiaries (see S. 476), S1326 [13FE] (see H.R. 2115), H3127 [8AP]

——— provide information on vaccines for seniors as part of the Medicare & You handbook and ensure treatment of cost-sharing for vaccines under part D is consistent with treatment under part B (see S. 1872), S3477 [13JN] (see H.R. 5076), H8826 [13NO]

——— provide low-income subsidy enrollees in part D with information about less expensive prescription drug plan options (see H.R. 4632), H8110 [11OC]

——— require certain manufacturers to report drug pricing information (see S. 2051), S4677 [28JN] (see H.R. 2087), H3099 [4AP]

——— require drug manufacturers to pay a rebate for certain drugs if the price of such drugs increases faster than inflation (see H.R. 4619), H8101 [8OC] (see H.R. 4663), H8111 [11OC]

——— require drug manufacturers to provide rebates for drugs furnished under part B for which the growth in average sales price has exceeded inflation (see S. 2081), S4773 [10JY]

——— require drug price concessions, incentive payments, and adjustments to be included in negotiated prices at the point-of-sale under part D (see S. 640), S1621 [4MR] (see H.R. 1034), H1458 [7FE]

——— require manufacturers of certain single-dose vial drugs payable under part-B to provide rebates relative to amounts of such drugs discarded (see S. 551), S1437 [25FE]

——— require prescription drug plan sponsors to include real-time benefit information as part of such sponsor’s electronic prescription program (see H.R. 3408, 3415), H5036 [21JN]

——— require prescription drug plans and Medicare Advantage prescription drug plans to report potential fraud, waste, and abuse to Dept. of HHS under part D (see S. 1505), S2924 [16MY]

——— require the Dept. of HHS to negotiate lower covered part D prescription drug prices for beneficiaries (see H.R. 275), H281 [8JA]

——— treat a pharmacy counter refusal as a coverage determination under part D (see S. 1861), S3476 [13JN] (see H.R. 3924), H7241 [23JY]

Medicare/Medicaid: eliminate cost-sharing relative to coverage of insulin as a covered part D drug under Medicare or as a covered outpatient drug under Medicaid (see H.R. 366), H356 [9JA]

——— lower prescription drug prices, improve transparency of pharmaceutical prices and transactions, lower patients’ out-of-pocket costs, and ensure accountability to taxpayers (see S. 2543), S5706 [25SE]

——— promote ability of beneficiaries to access their personal medical claim data through a mobile health record application (see H.R. 1390), H2270 [27FE]

——— provide Medicare Payment Advisory Commission and Medicaid and CHIP Payment and Access Commission with access to certain drug payment information, including certain rebate information (see S. 801), S1898 [14MR] (see H.R. 1264), H2031 [14FE] (see H.R. 1781), H2744 [14MR]

——— repeal medical device tax and extend certain programs and tax incentives (see S. 3001), S6904 [9DE]

——— require drug and biological product manufacturers to include truthful and non-misleading pricing information in any direct-to-consumer advertising (see S. 1437), S2787 [13MY]

Meningitis B Awareness Day: designate (see S. Res. 159), S2435 [11AP] (see H. Res. 313), H3256 [10AP]

National Academies of Sciences, Engineering, and Medicine: conduct review of deaths of certain veterans who committed suicide (see S. 2991), S6888 [5DE]

National Adult Hepatitis B Vaccination Awareness Day: designate (see S. Res. 177), S2516 [30AP] (see H. Res. 331), H3339 [30AP]

NIH: conduct or support further comprehensive research for creation of a universal influenza vaccine (see S. 570), S1493 [26FE] (see H.R. 1371), H2233 [26FE]

——— reauthorize innovation projects (see H.R. 4667), H8111 [11OC]

Office of the U.S. Trade Representative: establish position of Chief Pharmaceutical Negotiator responsible for trade negotiations and agreements relative to foreign governments that fail to reward U.S. pharmaceutical innovation (see H.R. 2209), H3252 [10AP]

Orphan Drug Act: affirm importance, commend life-saving accomplishments, and recognize need and continued support for research in development of therapies, treatments, and cures for rare diseases (see H. Res. 242), H2755 [18MR]

Patents: clarify and improve patent infringement litigation process for biological products to expedite getting generic drugs to market (see H.R. 3991), H7463 [25JY]

——— provide that a patent owner may not assert sovereign immunity as a defense in certain actions before the Patent and Trademark Office (see S. 440), S1275 [12FE]

Patient Protection and Affordable Care Act: repeal amendments which disqualify expenses for over-the-counter drugs under health savings accounts and health flexible spending arrangements (see S. 1089), S2328 [9AP]

Patient-Centered Outcomes Research Institute: reauthorize (see S. 2897), S6669 [19NO]

Public safety officers: provide opioid receptor antagonists, including naloxone, to first responders for personal use to prevent accidental overdose due to incidental contact with dangerous drugs (see H.R. 1823), H2754 [18MR]

Social Security: reform (see H.R. 5392), H10123 [11DE]

Sports: improve integrity and safety of horseracing by requiring a uniform anti-doping and medication control program enforced by an independent anti-doping organization (see S. 1488), S2884 [15MY]

——— improve integrity and safety of horseracing by requiring a uniform anti-doping and medication control program enforced by an independent Horseracing Anti-Doping and Medication Control Authority (see S. 1820), S3363 [12JN] (see H.R. 1754), H2742 [14MR]

Substance Abuse and Mental Health Services Administration: award grants to States to expand access to clinically appropriate services for opioid abuse, dependence, or addiction (see H.R. 1302), H2038 [15FE]

Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act: provide funding for programs and activities (see S. 2102), S4807 [11JY] (see H.R. 4460), H7901 [24SE]

Taxation: authorize designation of additional taxable vaccines (see S. 1654), S3105 [23MY] (see H.R. 1973), H2916 [28MR]

——— establish an excise tax on certain prescription drugs which have been subject to a price spike (see S. 378), S1131 [7FE] (see H.R. 1093), H1461 [7FE]

——— establish an excise tax on production and importation of opioid pain relievers and use such funds to provide and expand access to substance abuse treatment (see S. 425), S1133 [7FE] (see H.R. 4631), H8110 [11OC] (see H.R. 4793), H8387 [22OC]

——— include certain over-the-counter medical and menstrual care products as qualified medical expenses in order to allow use of health savings accounts and flexible spending accounts for such products (see H.R. 1922), H2884 [27MR]

——— prohibit deduction for prescription drug advertising and promotional expenses (see S. 73), S141 [10JA] (see H.R. 4711), H8226 [17OC]

——— provide a safe harbor for high deductible health plans without a deductible for certain inhalers (see H.R. 4716), H8226 [17OC]

Essays

State of the Union: Livia Greenberg, S795 [31JA]

——— Megan Benway, S766 [30JA]

Letters

Dept. of HHS demonstration program to test alternative pain management protocols to limit use of opioids in emergency departments: Vidor E. Friedman, American College of Emergency Physicians, H4639 [13JN]

Dept. of HHS negotiation of lower covered Medicare part D prescription drug prices for beneficiaries: Keith Hall, CBO, S3023 [22MY]

——— Senator Grassley, Committee on Finance (Senate), S3023 [22MY]

Lower Drug Costs Now Act: Sara Stewart, H10109 [11DE]

——— several biotechnology organizations, H10097 [11DE]

——— several pharmaceutical companies, H10130 [12DE]

Over-the-Counter Drug Safety, Innovation, and Reform Act: Senator Braun, S1893 [14MR]

Payment Commission Data Act: Francis J. Crosson, Medicare Payment Advisory Commission, H8526 [28OC]

Lists

Availability of medications in H.R. 3, Lower Drug Costs Now Act reference countries, H10099–H10101 [11DE]

Top Medicare Part B drugs not covered by Dept. of Veterans Affairs (excluding vaccines), H10099 [11DE], H10217 [12DE]

Memorandums

Medicare for All Act: Wen S. Shen, Congressional Research Service, S4750 [10JY]

Messages

Budget of the U.S. Government for Fiscal Year 2020: President Trump, S1760 [11MR], H2625 [11MR]

Motions

Dept. of HHS: establish Fair Price Negotiation Program to reduce drug prices, penalize certain companies, and prevent excessive price increases and establish out-of-pocket caps for Medicare (H.R. 3), consideration (H. Res. 758), H10044 [11DE]

——— establish Fair Price Negotiation Program to reduce drug prices, penalize companies that refuse to negotiate, and prevent excessive price increases and establish out-of-pocket caps for Medicare (H.R. 3), H10223 [12DE]

Health: reduce prescription drug prices, facilitate entry of generic and biosimilar products into the market, strengthen Federal exchanges, and reverse extension of short-term health plans (H.R. 987), H3904 [16MY]

Notices

Estimated budget effects of H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act, H3786 [14MY], H3921 [16MY]

Estimated budget effects of H.R. 1839, Medicaid Services Investment and Accountability Act, H2793 [25MR]

Intention to object to H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act: Senator Braun, S1910 [14MR]

Remarks in House

Abortion: prohibit chemical abortions performed without the presence of a health care provider (H.R. 4935), H8816 [13NO], H9064 [20NO]

Alliance for Substance Abuse Progress in Bartholomew County, IN: tribute, H5308 [10JY]

American Pharmacists Month: observance, H8600 [30OC]

Arkansas: tribute to Prescription for Life program, H5084 [25JN]

Boone Drug, Inc.: anniversary, H1169 [23JA], E99 [28JA]

Business and industry: prohibit biological product manufacturers from compensating biosimilar and interchangeable product companies to delay entry of biosimilar and interchangeable products into the market, H3800 [15MY], H3856 [16MY]

——— prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, H3800 [15MY], H3856 [16MY]

——— prohibit prescription drug manufacturers from compensating other companies to delay entry of generic drugs, biosimilar biological products, or interchangeable biological products into the market (H.R. 2375), H3296 [29AP], H3455 [7MY]

China: assessment as threat relative to economic and military expansion, unfair trade practices, theft of intellectual property, and human rights violations, H9251–H9254 [4DE]

Congress: accomplishments of the 116th Congress, H7248 [24JY]

——— legislative priorities, H8155 [16OC], H8708 [31OC]

——— recognize failure to pass legislation due to prioritization of impeachment inquiry against President Trump, H9152, H9153 [21NO]

Consumers: implement strategy to reduce prescription drug prices, H3464 [7MY], H3658–H3661 [9MY], H7094 [18JY], H8153 [16OC], H8303 [22OC]

Democratic Party: national agenda, H8837 [14NO], H9065 [20NO], H9125 [21NO]

Dept. of Agriculture: improve Supplemental Nutrition Assistance Program support for women, infants, and children impacted by substance use disorder (H.R. 5249), H9230 [4DE]

Dept. of Defense: ensure cultural competence and diversity are considered in recruitment and retention efforts for mental health providers, H5659 [11JY]

——— establish partnerships with academic health centers to reduce opioid dependency, develop new pain management methods, and advance technologies to improve lives of wounded veterans, H5658 [11JY]

——— include in each national defense strategy steps to strengthen the U.S. industrial base and to assure an uninterrupted supply of medicines (H.R. 4710), E1297 [17OC]

Dept. of HHS: add a new set of measures to Medicare Advantage program 5-star rating system in order to encourage increased access to biosimilar biological products, H10203, H10204 [12DE]

——— address opioid drug abuse epidemic, H10032 [11DE]

——— allow Dept. of Veterans Affairs to purchase drugs at Fair Price Negotiation Program prices, H10216, H10217 [12DE]

——— authorize a pilot program to develop, expand, and enhance commercialization of biomedical products, H10204, H10205 [12DE]

——— conduct a demonstration program to test alternative pain management protocols to limit use of opioids in emergency departments, H4639, H4640 [13JN]

——— ensure doctors have access to patients’ treatment history to prevent addiction relapses or harmful drug interactions and protect confidentiality of substance use disorder patient records (H.R. 2062), E397 [3AP]

——— ensure Fair Price Negotiation Program and Medicare changes to reduce drug prices will not result in fewer new drug applications for unmet medical needs and life-saving cures, H10223, H10224 [12DE]

——— ensure State plans for safe care of infants exposed to substances in utero do not unfairly target pregnant women who need to remain on certain medications, H3990 [20MY]

——— establish Fair Price Negotiation Program to reduce drug prices, penalize certain companies, and prevent excessive price increases and establish out-of-pocket caps for Medicare (H.R. 3), consideration (H. Res. 758), H10033–H10042 [11DE]

——— establish Fair Price Negotiation Program to reduce drug prices, penalize companies that refuse to negotiate, and prevent excessive price increases and establish out-of-pocket caps for Medicare (H.R. 3), H7854–H7857 [20SE], H7873 [24SE], H7996 [26SE], H8153 [16OC], H8207 [17OC], H8232, H8250, H8252 [18OC], H8371, H8374 [22OC], H8397, H8398 [23OC], H8592 [29OC], H8606, H8607, H8608 [30OC], H8682 [31OC], H8775 [12NO], H8792 [13NO], H8831, H8835, H8873 [14NO], H8884, H8905, H8906 [15NO], H8963, H8966, H9052–H9054 [19NO], H9157 [21NO], H9210 [3DE], H9288–H9290 [5DE], H9955, H9956 [10DE], H10020, H10022, H10023, H10025, H10026, H10027, H10031, H10032, H10033, H10096–H10122 [11DE], H10128, H10129–H10225, H10235 [12DE]

——— establish Fair Price Negotiation Program to reduce drug prices, penalize companies that refuse to negotiate, and prevent excessive price increases and establish out-of-pocket caps for Medicare (H.R. 3), motion to recommit, H10223, H10224 [12DE]

——— establish grant program for States to reduce unnecessary costs and administrative burdens in health care, H10213, H10214 [12DE]

——— incentivize low-cost drug options and generic competition and extend funding for community health centers, National Health Service Corps, teaching health centers and other public health programs (H.R. 2700), H3804 [15MY], H3856, H3857 [16MY], H4013 [21MY]

——— include coverage for Federal employee health plans in Fair Price Negotiation Program to reduce drug prices, H10215, H10216 [12DE]

——— increase maximum number of special masters allowed in U.S. Court of Federal Claims to hear cases under National Vaccine Injury Compensation Program (H.R. 3003), E665 [23MY]

——— medication-assisted treatment of opioid abuse funding, H4561 [12JN]

——— Minority HIV/AIDS Fund funding, H4621, H4622 [12JN]

——— negotiate prices of prescription drugs furnished under Medicare part D and mandate production of generic versions of drugs if pharmaceutical companies fail to negotiate in good faith (H.R. 1046), H2947 [2AP], H3309 [30AP]

——— prevent spread pricing in Medicaid by pharmacy benefit managers and increase funding for NIH clinical trials, H10218 [12DE]

——— report on extent to which increases in prices of commonly prescribed drugs has caused individuals with health insurance to forego needed treatment, H3885, H3886 [16MY]

——— require another Senate-confirmed officer within the Dept., to carry out drug price negotiation duties should the Sec. of HHS have a conflict of interest, H10205, H10206 [12DE]

——— require drug manufacturers to submit a transparency and justification report prior to increasing certain drug prices (H.R. 2069), H8607 [30OC], H8911 [18NO]

——— require drug manufacturers to submit a transparency and justification report prior to increasing certain drug prices (H.R. 2296), H10118 [11DE]

——— require manufacturers to justify drug price spikes and high launch prices and report on drug, device, biological, and medical supply product samples provided to health care providers (H.R. 2113), H3429 [2MY]

——— require persons who undertake federally funded research and development of drugs to enter into reasonable pricing agreements (H.R. 4640), H10140 [12DE]

——— research on certain Schedule I drugs that have shown promise in treating critical diseases funding, H4612, H4613 [12JN]

——— Substance Abuse and Mental Health Services Administration grants to States to develop best practices for emergency room treatment of opioid overdose patients funding, H4564 [12JN]

——— Substance Abuse Prevention and Treatment Block Grants and State Opioid Response Grants program funding, E849 [26JN]

Dept. of Veterans Affairs: ensure access to child care for veterans while receiving substance or drug abuse counseling at a departmental facility, H1424 [7FE]

Depts. of HHS and Education: ensure access by students and faculty of pharmacy schools to information on use and availability of generic drugs and biosimilar biological products, H3882 [16MY]

Discount Drug Mart, Inc.: anniversary, E516 [1MY]

Diseases and disorders: facilitate effective research on, and treatment of, neglected tropical diseases through coordinated international efforts, H10594 [17DE]

——— facilitate effective research on, and treatment of, neglected tropical diseases through coordinated international efforts (H.R. 3460), H9194–H9197 [3DE]

Drugs: acknowledge impact of high cost of prescription drugs on communities of color and persons living in rural or sparsely populated areas, H10208–H10210 [12DE]

——— address fentanyl abuse, H3852 [16MY]

——— address prescription opioid and heroin abuse, H374 [10JA], H548 [15JA], H2106 [26FE], H7993, H8043 [26SE], H9259 [5DE]

——— address rising cost of insulin, H2946 [2AP], H9248 [4DE], E1030 [2AU]

——— end Federal ban of medical marijuana, allow importation of certain derivatives, enable medicinal research, and allow prescription to veterans (H.R. 127), E7 [3JA]

——— facilitate responsible, informed dispensing of controlled substances and other prescribed medications (H.R. 4810), E1330 [23OC]

——— provide for opioid use disorder prevention, recovery, and treatment, E1330 [23OC]

——— require disclosure of list prices of prescription drugs and biological products in direct-to-consumer television advertising, H10214, H10215 [12DE]

FDA: clarify regulatory framework relative to certain nonprescription drugs that are marketed without an approved new drug application (H.R. 269), H237–H266 [8JA]

——— clarify regulatory framework relative to certain nonprescription drugs that are marketed without an approved new drug application (H.R. 3443), E971, E977 [24JY]

——— clarify types of patents on safe and effective drug list, require list of applicable exclusivities for listed drugs, update patent sponsor requirements, and reform patent list guidelines (H.R. 1503), H3486–H3488 [8MY], H4401 [11JN]

——— increase competition in generic drug market by removing barriers for a second generic drug to come to market created by exclusivity period granted to a first generic drug application, H3800 [15MY], H3857, H3860 [16MY]

——— increase competition in generic drug market by removing barriers for a second generic drug to come to market created by exclusivity period granted to a first generic drug application (H.R. 938), H3429 [2MY], H10118 [11DE]

——— invest in qualified clinical testing for high-risk, high-reward drugs that address unmet medical needs to treat rare and life-threatening diseases, H10210, H10211 [12DE]

——— prohibit abusive delay tactics by pharmaceutical companies to block entry of generic drugs and biosimilar biological products from the market, H3858, H3864, H3865, H3873 [16MY]

——— prohibit abusive delay tactics by pharmaceutical companies to block entry of generic drugs and biosimilar biological products from the market (H.R. 965), H3429 [2MY], H3455 [7MY], H3911 [16MY]

——— prohibit funding to finalize, implement, or enforce draft guidance on drug products labeled as homeopathic, H4943, H4944 [20JN]

——— provide for publication of a list of licensed biological products (H.R. 1520), H3485, H3486 [8MY]

——— restrict direct-to-consumer drug advertising, H8966 [19NO]

FTC: deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar and foster competition and facilitate review of drug petitions filed in good faith (H.R. 2374), H3455 [7MY]

——— study role of intermediaries in the pharmaceutical supply chain and merger activity and provide Congress with appropriate policy recommendations (H.R. 2376), H3455 [7MY]

Hamilton County, OH: tribute to efforts to address prescription opioid abuse, H2721 [14MR]

Health: accelerate discovery, development, and delivery of 21st century lifesaving cures and devices, E41 [14JA]

——— address high costs of health care, prescription drugs, and health insurance coverage, H4687 [13JN], H5314 [10JY], H5925 [17JY], H7166 [23JY], H8463 [28OC]

——— recognize importance of vaccinations and immunizations, H3287 [29AP]

——— reduce prescription drug prices, facilitate entry of generic and biosimilar products into the market, strengthen Federal exchanges, and reverse extension of short-term health plans (H.R. 987), H3715 [10MY], H3731 [14MY], H3800 [15MY], H3851, H3852, H3853–H3911, H3913 [16MY], H4123 [23MY], H4401 [11JN], H5085 [25JN], H5175 [26JN], H7693 [12SE], H9248 [4DE], E623 [17MY]

——— reduce prescription drug prices, facilitate entry of generic and biosimilar products into the market, strengthen Federal exchanges, and reverse extension of short-term health plans (H.R. 987), consideration (H. Res. 377), H3801–H3813 [15MY]

——— reduce prescription drug prices, facilitate entry of generic and biosimilar products into the market, strengthen Federal exchanges, and reverse extension of short-term health plans (H.R. 987), corrections in engrossment, H3911 [16MY]

——— reduce prescription drug prices, facilitate entry of generic and biosimilar products into the market, strengthen Federal exchanges, and reverse extension of short-term health plans (H.R. 987), motion to recommit, H3908, H3909 [16MY]

——— use of technology to improve services and reduce costs of health care, H2705–H2707 [13MR], H3062–H3064 [3AP], H4306–H4308 [4JN], H7828 [19SE], H8591–H8593 [29OC], H8873 [14NO], H9288–H9290 [5DE]

House of Representatives: legislative priorities, H3089 [4AP], H3240 [10AP], H3851 [16MY], H7718 [17SE], H8377 [22OC], H8553 [29OC], H12152, H12180, H12181 [18DE]

Insurance: establish a public health plan (H.R. 2000), H2947 [2AP], H5313 [10JY]

——— require health plan oversight of pharmacy benefit manager services (H.R. 5304), H10204 [12DE]

International Self-Care Day: observance, E977 [24JY]

Medicaid: extend certain spousal impoverishment protections, provide State option of coordinated care for children with medically complex conditions, and prevent misclassification of drugs in drug rebate program (H.R. 1839), H2773–H2780, H2781 [25MR], H3224 [10AP], E354 [26MR]

Medicare: allow the Dept. of HHS to negotiate lower covered part D prescription drug prices for beneficiaries, H7997 [26SE]

——— negotiate prices of excessively costly life-sustaining prescription drugs (H.R. 5039), H8836 [14NO]

——— provide for a cap on beneficiary liability under part D (H.R. 4649), H8232 [18OC], H8607 [30OC]

——— provide for automatic qualification of certain Medicaid beneficiaries for premium and cost-sharing subsidies under part D, H10038 [11DE]

——— provide for automatic qualification of certain Medicaid beneficiaries for premium and cost-sharing subsidies under part D (H.R. 4661), H8207 [17OC]

——— provide for certain rules on treatment of eligible retirement plans in determining eligibility of individuals for premium and cost-sharing subsidies under part D, H10135 [12DE]

——— provide for certain rules on treatment of eligible retirement plans in determining eligibility of individuals for premium and cost-sharing subsidies under part D (H.R. 4655), H8397 [23OC]

——— provide for intelligent assignment of certain subsidy eligible individuals auto-enrolled under prescription drug plans and Medicare Advantage prescription drug plans, H10110 [11DE]

——— provide for intelligent assignment of certain subsidy eligible individuals auto-enrolled under prescription drug plans and Medicare Advantage prescription drug plans (H.R. 4669), H8148 [16OC]

——— provide greater transparency of discounts provided by drug manufacturers by requiring Pharmacy Benefit Managers to disclose aggregate rebates and what proportion of those rebates go to beneficiaries (H.R. 2115), H8516–H8519 [28OC], E1366 [29OC], E1383 [31OC]

——— require drug manufacturers to pay a rebate for certain drugs if the price of such drugs increases faster than inflation, H10134, H10201 [12DE]

——— require drug price concessions, incentive payments, and adjustments to be included in negotiated prices at the point-of-sale under part D, H3658–H3661 [9MY]

——— require drug price concessions, incentive payments, and adjustments to be included in negotiated prices at the point-of-sale under part D (H.R. 1034), H8961 [19NO]

——— require the Dept. of HHS to negotiate lower covered part D prescription drug prices for beneficiaries (H.R. 275), H2379 [6MR]

Medicare/Medicaid: eliminate cost-sharing relative to coverage of insulin as a covered part D drug under Medicare or as a covered outpatient drug under Medicaid (H.R. 366), H3311 [30AP], H3866 [16MY], H7996 [26SE]

——— provide Medicare Payment Advisory Commission and Medicaid and CHIP Payment and Access Commission with access to certain drug payment information, including certain rebate information (H.R. 1781), H3800 [15MY], H8519, H8526, H8527 [28OC]

National Academy of Medicine: study role of Federal funding and research in drug development, H3878 [16MY]

National Association of Chain Drug Stores: tribute to annual RxIMPACT Day on Capitol Hill, E223 [27FE]

National Opioid Awareness Week: observance, H7605 [11SE]

National Pharmacist Day: observance, H366 [10JA]

National Prescription Drug Take Back Day: observance, H3296 [29AP]

Office of National Drug Control Policy: Drug-Free Communities Support Program funding, H5187 [26JN]

Patient Protection and Affordable Care Act: impact of implementation on health care, coverage, costs, and accessibility, H9248 [4DE]

——— provide opioid specific education and training for navigators and certified application counselors, H3879 [16MY]

Pennsylvania State University: tribute to Consortium To Combat Substance Abuse, H3296 [29AP]

Right To Try Act: implementation, H9126 [21NO]

Safe Kids North Carolina (organization): anniversary, E573 [10MY]

Social Security: reform (H.R. 5392), H10021 [11DE]

Sowing Seeds of Hope, Inc.: tribute, E1077 [27AU]

Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act: anniversary, E1350 [28OC]

Trump, President: evaluation of administration relative to health care, H9248 [4DE]

——— State of the Union Message, H1367 [6FE]

U.S. Export Finance Agency: prohibit assistance to foreign state-owned entities if the foreign governments are found not to be cooperating with U.S. to prevent synthetic opioid trafficking, H8864, H8865 [14NO]

——— prohibit transactions with individuals involved in sanctionable activities related to illegal trafficking of synthetic opioids, H8862, H8863 [14NO]

University of South Carolina: College of Pharmacy winners of MEDISCA, Inc., Student Pharmacist Compounding Competition, E677 [28MY]

World Pharmacists’ Day: observance, H7907 [25SE]

Remarks in Senate

Business and industry: improve access to generic prescription drugs, S5159 [30JY], S6527 [13NO]

——— prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market (S. 64), S2001 [26MR], S6527 [13NO]

Capitol Building and Grounds: authorize use of atrium in the Philip A. Hart Senate Office Building for National Prescription Drug Take Back Day, a semiannual event for the DEA (S. Res. 359), S5853 [16OC]

——— authorize use of Hart Senate Office Building atrium for DEA National Drug Take Back Day event (S. Res. 158), S2392 [10AP]

Comprehensive Addiction and Recovery Act: impact, S1664–S1666 [5MR], S2737–S2739 [8MY]

——— reauthorize and expand, S7224 [19DE]

Congress: accomplishments of the 115th Congress, S2798 [14MY]

——— legislative priorities, S13–S17 [3JA]

Consumers: implement strategy to reduce prescription drug prices, S780 [31JA], S1458 [26FE], S1501 [27FE], S1864 [14MR], S2470 [29AP], S2716, S2733 [8MY], S3809 [19JN], S4488, S4491 [25JN], S4706–S4708, S4710 [9JY], S4751–S4764 [10JY], S4830, S4835 [16JY], S5009 [23JY], S5094 [25JY], S5157–S5159, S5177 [30JY], S5346–S5349 [9SE], S5480 [12SE], S5887–S5889 [17OC], S6085 [23OC], S6218 [29OC], S6309 [31OC], S6467 [7NO]

DEA: allow community addiction treatment facilities and community mental health facilities to register to dispense controlled substances through telemedicine (S. 2244), S6280 [30OC]

——— report certain information on distribution of opioids to assist in identifying suspicious orders and hold manufacturers and distributors accountable who fail to report and stop suspicious orders (S. 3070), S7116 [17DE]

Dept. of HHS: allow personal importation of safe and affordable drugs from approved pharmacies in Canada (S. 61), S2001 [26MR], S2868 [15MY]

——— authorize State Opioid Response Grants program and allow use of funding to address methamphetamine and cocaine abuse (S. 1925), S4173 [20JN], S5091 [25JY], S7224 [19DE]

——— establish an annual reference price for insulin products for purposes of Federal health programs (S. 2817), S6479 [7NO]

——— establish Fair Price Negotiation Program to reduce drug prices, penalize companies that refuse to negotiate, and prevent excessive price increases and establish out-of-pocket caps for Medicare (H.R. 3), S5587 [19SE], S5619 [23SE], S5636 [24SE], S5716 [26SE], S5934 [22OC], S6205 [29OC], S6271 [30OC], S6523 [13NO], S6958 [11DE], S7037 [16DE]

——— establish reference prices for prescription drugs and require drug companies to offer drugs at such prices as condition of participation in Federal health programs (S. 1987), S4569 [26JN]

——— make Indian tribes eligible for State Targeted Response to the Opioid Crisis Grants and expand use to include methamphetamine abuse, S6279 [30OC]

——— mitigate drug shortages by prioritizing review of new drug applications, inspections, and reasons for shortages and assess national security threats associated with drug and ingredient shortages (S. 2723), S6245 [29OC]

——— require pharmacies and insurance companies to improve transparency of prescription drug costs and prohibit drug manufacturers from charging U.S. consumers more for drugs than certain foreign customers (S. 977), S4754 [10JY]

Dept. of Veterans Affairs: eliminate copayments for medicines relative to preventive health services (S. 1573), S6591 [14NO]

——— eliminate copayments for medicines relative to preventive health services (S. 1573), unanimous-consent request, S6591 [14NO]

Drugs: address prescription opioid and heroin abuse, S1585 [28FE], S1663–S1666 [5MR], S2737–S2739 [8MY], S2918 [16MY], S3147 [3JN], S3305 [11JN], S3464 [13JN], S5089–S5091 [25JY], S5126 [29JY], S5220 [31JY], S5436 [11SE]

——— address rising cost of insulin, S1639 [5MR], S4761–S4764 [10JY]

——— prohibit pharmacy benefit managers and insurers from receiving rebates for insulin products for which the manufacturer has complied with list price reduction requirements and require certain deductible waivers (S. 2199), S5158 [30JY], S6527 [13NO]

——— provide for opioid use disorder prevention, recovery, and treatment, S3147 [3JN], S3305 [11JN], S5028, S5033 [24JY], S5437 [11SE]

——— require disclosure of list prices of prescription drugs and biological products in direct-to-consumer television advertising, S3809 [19JN], S4707 [9JY], S4831 [16JY]

——— require drug manufacturers to disclose contributions to patient advocacy organizations and other health care organizations that engage in lobbying, S5127 [29JY]

——— require drug manufacturers to disclose prices of prescription drugs in any direct-to-consumer advertising and marketing to practitioners of a drug, S1865 [14MR], S2733 [8MY], S3177 [4JN], S6418 [6NO], S6459 [7NO], S6498 [12NO], S6521, S6522 [13NO]

——— streamline, coordinate and expand research and foster increased communication between doctors and patients relative to cannabidiol and other marijuana components and their medical benefits (S. 2032), S4633 [27JN]

FDA: clarify regulatory framework relative to certain nonprescription drugs that are marketed without an approved new drug application (H.R. 269), S106 [9JA], S111 [10JA]

——— clarify regulatory framework relative to certain nonprescription drugs that are marketed without an approved new drug application (S. 2740), S6915, S6918, S6921, S6944, S6945 [10DE]

——— clarify regulatory framework relative to certain nonprescription drugs that are marketed without an approved new drug application (S. 2740), unanimous-consent agreement, S6900 [9DE]

——— hold pharmaceutical companies accountable for illegal marketing and distribution of opioid products and for their role in creating and exacerbating the opioid epidemic, S4883–S4885 [17JY]

——— increase competition in generic drug market by removing barriers for a generic drug to come to market by curbing patent manipulation by brand name drug manufacturers (S. 1209), S2854–S2856 [15MY]

——— increase reporting transparency and accountability relative to user fees, S6945 [10DE]

——— prohibit abusive delay tactics by pharmaceutical companies to block entry of generic drugs and biosimilar biological products from the market, S2716 [8MY], S4755 [10JY], S5158 [30JY], S6527 [13NO]

——— prohibit abusive delay tactics by pharmaceutical companies to block entry of generic drugs and biosimilar biological products from the market (S. 340), S868, S873 [5FE], S875 [6FE], S2366 [10AP], S2868, S2872 [15MY], S4753 [10JY], S5177 [30JY]

——— require manufacturers of approved biological products to disclose and list patents, biosimilarity, and exclusivity information relative to their products and promote biosimilar competition, S5158 [30JY], S6527 [13NO]

——— require manufacturers of approved biological products to disclose and list patents, biosimilarity, and exclusivity information relative to their products and promote biosimilar competition (S. 659), S1752–S1754 [11MR], S2252 [4AP], S2872 [15MY]

——— shorten monopoly periods for prescription drugs that are subjects of sudden price hikes (S. 366), S1501 [27FE]

FDA Modernization Act: implementation, S6945 [10DE]

FTC: deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar and foster competition and facilitate review of drug petitions filed in good faith (S. 1224), S2868 [15MY], S4488 [25JN], S4710 [9JY], S5177 [30JY]

——— prohibit anticompetitive use of patents by drug product manufacturers (S. 1416), S2870 [15MY], S3180 [4JN], S4488 [25JN], S4762, S4763 [10JY], S5009 [23JY], S5506 [17SE], S6217 [29OC], S6272 [30OC], S6368 [5NO], S6459 [7NO], S6497 [12NO], S6520–S6524, S6527 [13NO], S6640 [19NO], S6742 [21NO]

——— prohibit anticompetitive use of patents by drug product manufacturers (S. 1416), unanimous-consent request, S6521–S6523 [13NO], S6967, S6968 [11DE]

——— study role of intermediaries in the pharmaceutical supply chain and merger activity and provide Congress with appropriate policy recommendations (S. 1227), S4488 [25JN], S4753 [10JY], S5177 [30JY]

Gottlieb, Scott: assessment of tenure as FDA Commissioner, S2321 [9AP]

Health: address high costs of health care, prescription drugs, and health insurance coverage, S2251 [4AP], S2755 [9MY], S5436 [11SE], S6256–S6259 [29OC], S6975 [11DE]

——— improve insurance access and affordability, strengthen protections for individuals with preexisting conditions, and terminate sale of short-term, limited duration insurance plans, S6688 [20NO]

——— lower health care costs by ending surprise medical bills, reducing drug prices, and improving health care transparency, public health, and exchange of health information (S. 1895), S4710 [9JY], S4752, S4755 [10JY], S4834 [16JY], S5158, S5165–S5167 [30JY], S5436 [11SE], S6527 [13NO]

——— recognize importance of vaccinations and immunizations (S. Res. 165), S2455 [11AP]

——— reduce prescription drug prices, facilitate entry of generic and biosimilar products into the market, strengthen Federal exchanges, and reverse extension of short-term health plans (H.R. 987), S6934 [10DE]

Insurance: ensure that health insurance issuers and group health plans do not prohibit pharmacy providers from providing certain information to enrollees, S4754 [10JY], S5158 [30JY], S6526 [13NO]

——— establish a public health plan (S. 981), S4713 [9JY]

——— prohibit health plans and pharmacy benefit managers from restricting pharmacies from informing individuals regarding prices for certain drugs and biologicals, S4755 [10JY]

Medicaid: extend certain spousal impoverishment protections, provide State option of coordinated care for children with medically complex conditions, and prevent misclassification of drugs in drug rebate program (H.R. 1839), S2203 [2AP]

——— prevent misclassification of drugs for purposes of the drug rebate program (S. 205), S2470 [29AP], S5279 [1AU]

——— prevent spread pricing by pharmacy benefit managers, S5121 [29JY]

Medicare: allow the Dept. of HHS to negotiate lower covered part D prescription drug prices for beneficiaries, S3022–S3024 [22MY], S3353 [12JN], S3814 [19JN], S4491 [25JN], S4835 [16JY], S6085 [23OC], S6523 [13NO], S6689 [20NO]

——— allow the Dept. of HHS to negotiate lower covered part D prescription drug prices for beneficiaries (S. 62), S2001 [26MR], S2871 [15MY]

——— ensure equal access of beneficiaries to community pharmacies in underserved areas as network pharmacies under Medicare prescription drug coverage, S4754 [10JY]

——— establish part E public health plans available to everyone (S. 1261), S2561 [1MY]

——— establish Universal Medicare Program to provide comprehensive health insurance coverage for all U.S. residents, S896 [6FE]

——— reform application process of direct and indirect remuneration fees within part D prescription drug program, S4754 [10JY]

——— require manufacturers of certain single-dose vial drugs payable under part-B to provide rebates relative to amounts of such drugs discarded (S. 551), S1864 [14MR]

——— require prescription drug plans and Medicare Advantage prescription drug plans to report potential fraud, waste, and abuse to Dept. of HHS under part D (S. 1505), S3180 [4JN]

Medicare/Medicaid: improve drug programs, protect from drastic increases in manufacturer drug prices, increase transparency of pharmacy benefit manager practices, and allow payment for certain treatments, S5121, S5126 [29JY], S5177 [30JY], S5207, S5221 [31JY], S5480 [12SE]

——— lower prescription drug prices, improve transparency of pharmaceutical prices and transactions, lower patients’ out-of-pocket costs, and ensure accountability to taxpayers (S. 2543), S5888 [17OC], S6179 [28OC], S6205 [29OC], S6268 [30OC], S6375 [5NO], S6411 [6NO], S6525–S6527 [13NO], S6897 [9DE], S7037 [16DE], S7123 [18DE]

Mental health: improve outreach and access to care, S5351 [9SE]

National Prevention Week: observance, S2918 [16MY]

Patents: provide that a patent owner may not assert sovereign immunity as a defense in certain actions before the Patent and Trademark Office (S. 440), S4753 [10JY]

Patient Protection and Affordable Care Act: impact of implementation on health care, coverage, costs, and accessibility, S7011 [12DE]

Pharmaceuticals: implement strategy to reduce prescription drug prices, S2286 [8AP], S2867–S2872 [15MY]

Senate: legislative priorities, S2799 [14MY], S3032 [22MY], S6352 [31OC], S6582, S6590 [14NO], S6640–S6642 [19NO], S6868 [5DE]

Senate Caucus on International Narcotics Control: Marijuana and America’s Health hearing, S5934 [22OC]

Social Security: provide for transparency in the relationship between physicians and manufacturers of drugs, devices, or medical supplies for which payment is made under certain programs, S1888 [14MR]

Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act: impact, S6135 [24OC], S6274–S6280 [30OC]

——— impact on communities devastated by opioid epidemic, S3147 [3JN]

——— provide funding for programs and activities (S. 2102), S5437 [11SE]

Taxation: establish an excise tax on production and importation of opioid pain relievers and use such funds to provide and expand access to substance abuse treatment (S. 425), S2868 [15MY]

——— prohibit deduction for prescription drug advertising and promotional expenses, S5126 [29JY]

——— prohibit deduction for prescription drug advertising and promotional expenses (S. 73), S5221 [31JY]

Trump, President: evaluation of administration relative to health care, S6317 [31OC], S6589 [14NO], S6688 [20NO]

U.S.-Mexico-Canada Agreement (USMCA): impact on prescription drug prices, S6377 [5NO]

Reports filed

Affordable Prescriptions for Patients Act: Committee on the Judiciary (Senate) (S. 1416), S4676 [28JN]

Bringing Low-Cost Options and Competition While Keeping Incentives for New Generics (BLOCKING) Act: Committee on Energy and Commerce (House) (H.R. 938) (H. Rept. 116–46), H3438 [2MY]

Consideration of H.R. 3, Lower Drug Costs Now Act and H.R. 5038, Farm Workforce Modernization Act: Committee on Rules (House) (H. Res. 758) (H. Rept. 116–334), H10015 [10DE]

Consideration of H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act: Committee on Rules (House) (H. Res. 377) (H. Rept. 116–61), H3787 [14MY]

Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act: Committee on Energy and Commerce (House) (H.R. 965) (H. Rept. 116–55), H3726 [10MY]

——— Committee on the Judiciary (House) (H.R. 965) (H. Rept. 116–55), H3726 [10MY], H3922 [16MY]

Lower Drug Costs Now Act: Committee on Education and Labor (House) (H.R. 3) (H. Rept. 116–324), H9386 [9DE]

——— Committee on Energy and Commerce (House) (H.R. 3) (H. Rept. 116–324), H9345 [6DE]

——— Committee on Ways and Means (House) (H.R. 3) (H. Rept. 116–324), H9345 [6DE]

Lower Health Care Costs Act: Committee on Health, Education, Labor, and Pensions (Senate) (S. 1895), S4698 [8JY]

More Efficient Tools To Realize Information for Consumers (METRIC) Act: Committee on Energy and Commerce (House) (H.R. 2296) (H. Rept. 116–215), H7900 [24SE]

Orange Book Transparency Act: Committee on Energy and Commerce (House) (H.R. 1503) (H. Rept. 116–47), H3438 [2MY]

Over-the-Counter Monograph Safety, Innovation, and Reform Act: Committee on Health, Education, Labor and Pensions (Senate) (S. 2740), S6391 [5NO]

Payment Commission Data Act: Committee on Energy and Commerce (House) (H.R. 1781) (H. Rept. 116–257), H8537 [28OC]

Prescription Drug Pricing Reduction Act: Committee on Finance (Senate) (S. 2543) (S. Rept. 116–120), S5705 [25SE]

Prescription Pricing for the People Act: Committee on the Judiciary (Senate) (S. 1227), S4676 [28JN]

Preserving Access to Cost Effective Drugs (PACED) Act: Committee on the Judiciary (Senate) (S. 440), S4676 [28JN]

Protecting Consumer Access to Generic Drugs Act: Committee on Energy and Commerce (House) (H.R. 1499) (H. Rept. 116–52), H3725 [10MY]

Purple Book Continuity Act: Committee on Energy and Commerce (House) (H.R. 1520) (H. Rept. 116–48), H3447 [3MY]

Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act: Committee on the Judiciary (Senate) (S. 1224), S4676 [28JN]

Statements

Address Rising Cost of Insulin: Jonathan Chappel, S4763 [10JY]

——— Kathryn Nagel, S4762 [10JY]

——— Kristen Whitney Daniels, T1International (organization), S4763 [10JY]

Lower Drug Costs Now Act: Executive Office of the President, H10098 [11DE]

Lower Health Care Costs Act: Senator Alexander, Committee on Health, Education, Labor, and Pensions (Senate), S4623 [27JN]

Managing Pain During the Opioid Crisis: Senator Alexander, Committee on Health, Education, Labor, and Pensions (Senate), S2510 [30AP]

Vaccines Saves Lives—What Is Driving Preventable Disease Outbreaks: Senator Alexander, Committee on Health, Education, Labor, and Pensions (Senate), S2509 [30AP]

Tables

Estimated pay-as-you-go effects of H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act, H3786 [14MY], H3921 [16MY]

Estimated pay-as-you-go effects of H.R. 1839, Medicaid Services Investment and Accountability Act, H2793 [25MR]

Top opioid distributors and manufacturers 2006 through 2012, S4884 [17JY]

Testimonies

Opioid Epidemic: Beth Tanzman, Vermont Blueprint for Health, Dept. of Vermont Health Access, S1586 [28FE]

Texts of

H. Res. 377, consideration of H.R. 5, Equality Act, H.R. 312, Mashpee Wampanoag Tribe Reservation Reaffirmation Act, and H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act, H3801 [15MY]

H. Res. 758, consideration of H.R. 3, Lower Drug Costs Now Act and H.R. 5038, Farm Workforce Modernization Act, H10033 [11DE]

H.R. 3, Lower Drug Costs Now Act, H10141–H10167 [12DE]

H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act, H3868–H3873 [16MY]

H.R. 1503, Orange Book Transparency Act, H3486 [8MY]

H.R. 1520, Purple Book Continuity Act, H3485 [8MY]

H.R. 1781, Payment Commission Data Act, H8526 [28OC]

H.R. 1839, Medicaid Services Investment and Accountability Act, H2773–H2776 [25MR]

H.R. 2115, Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act, H8516 [28OC]

H.R. 3460, End Neglected Tropical Diseases Act, H9194 [3DE]

S. 366, Forcing Limits on Abusive and Tumultuous (FLAT) Prices Act, S921 [6FE]

S. 551, Recovering Excessive Funds for Unused and Needless Drugs (REFUND) Act, S1439 [25FE]

S. 1437, Drug-Price Transparency in Communications (DTC) Act, S2791 [13MY]

S. 1488, Racehorse Doping Ban Act, S2889 [15MY]

S. 2103, Affordable Insulin Approvals Now Act, S4809 [11JY]

S. 2400, Expanding Cannabis Research and Information Act, S5253 [31JY]

S. 2650, Medicare Prescription Drug Savings and Choice Act, S5924 [21OC]

S. 2740, Over-the-Counter Monograph Safety, Innovation, and Reform Act, S6921–S6930 [10DE]

S. Res. 158, use of Hart Senate Office Building atrium for DEA National Drug Take Back Day event, S2391 [10AP]

S. Res. 159, Meningitis B Awareness Day, S2439 [11AP]

S. Res. 165, recognize importance of vaccinations and immunizations, S2442 [11AP]

S. Res. 177, National Adult Hepatitis B Vaccination Awareness Day, S2524 [30AP]

S. Res. 273, support the right to affordable, quality health care, S4732 [9JY]

S. Res. 359, use of Philip A. Hart Senate Office Building atrium for DEA National Prescription Drug Take Back Day, S5851 [16OC]